SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-18-000247
Filing Date
2018-03-14
Accepted
2018-03-14 16:25:20
Documents
3
Group Members
ORBIMED CAPITAL GP V LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss83923_sc13da.htm SC 13D/A 128976
2 JOINT FILING AGREEMENT ss83923_ex9901.htm EX-99.1 33029
3 FORM OF LOCK-UP AGREEMENT ss83923_ex9902.htm EX-99.2 48821
  Complete submission text file 0000947871-18-000247.txt   212365
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Subject) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89443 | Film No.: 18689766
SIC: 2834 Pharmaceutical Preparations